Claim

In an Ethiopian phase II randomized trial of 183 adults with localized Leishmania aethiopica cutaneous leishmaniasis, single-session thermotherapy and weekly intralesional sodium stibogluconate had comparable intention-to-treat cure rates, while per-protocol final cure favored drug treatment; no serious adverse events occurred.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 17975

40 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluablea comma-separated series may list several propositions

Referenced 121 times: checked 2, looked up by assistants 0, viewed 89, shared 30. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Supported

Score: 0.9468 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

2 independent evidence lineages · review checks 1 of 4 · stability HIGH

Main unresolved issue: 4 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:93470326-1b64-8f1c-9bd1-6cd20acba021

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from link.springer.com and scienmag.com was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The trial found no significant intention-to-treat cure difference, a per-protocol final-cure advantage for drug treatment, and no serious adverse events. weight 1.800000 evidence

Suppressed as dependent: The packet directly supports the sample, intention-to-treat comparison, per-protocol result, and absence of serious adverse events.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Leans supported.

Hide calculation

0.9468 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 4 sources, 2 independent lineages

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:6515468c8087bf2dc54e7cc9d53f872b016295de803b704af7d7a4df097eb174

Last changed at entry seq 25378; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

Link	Working	Weight	Counted as
f3e8f5bc qualify	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (non directional)
28ae72b7 support	relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	1.800000
1897294b support	relevance STRONG 1.2 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.080000	1.080000
434d220c support	relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (dependent strongest only, kept 28ae72b7)

prior 0.50 → log-odds 0.000000 + 2.880000 (the counted weights) = 2.880000 → probability 0.9468

Under neighbouring settings of the same model: 0.8825 to 0.9769, a spread of 0.0944.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In an Ethiopian phase II randomized trial of 183 adults with localized Leishmania aethiopica cutaneous leishmaniasis, single-session thermotherapy and weekly...” · 1 claim · 29 September 2026
“In an Ethiopian phase II randomized trial of 183 adults with localized Leishmania aethiopica cutaneous leishmaniasis, single-session thermotherapy and weekly...” · 1 claim · 29 September 2026

Evidence for

The trial found no significant intention-to-treat cure difference, a per-protocol final-cure advantage for drug treatment, and no serious adverse events.

From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The packet directly supports the sample, intention-to-treat comparison, per-protocol result, and absence of serious adverse events.

From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Independent reporting reproduces the trial’s intention-to-treat comparability and per-protocol advantage for intralesional sodium stibogluconate.

From Single-Session Heat Treatment Matches Standard Drug Therapy for Disfiguring Skin Disease in Ethiopia Read 2026-09-29 Relevance STRONG Steps 0 Counted

Secondary report also describes the 183-participant Ethiopian trial and its safety/adherence context.

Evidence against

None.

Qualifications

The comparison applies to adults with uncomplicated localized parasitologically confirmed disease and specified regimens assessed at day 90/105 and day 180.

From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Adds eligibility, treatment dosing, and endpoint timing/analysis scope.

Suppressed as dependent

Evidence	Group	Kept instead
30879a77		28ae72b7

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	f3e8f5bc, 28ae72b7, 434d220c

Summary

Supported. The main support is: The trial found no significant intention-to-treat cure difference, a per-protocol final-cure advantage for drug treatment, and no serious adverse events. e4e290fb

1 further item repeats the same origin and is not independent evidence. 30879a77

Qualifier: The comparison applies to adults with uncomplicated localized parasitologically confirmed disease and specified regimens assessed at day 90/105 and day 180. 64abec3e

Review checks: 1 of 4. coverage:93470326-1b64-8f1c-9bd1-6cd20acba021

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
17975	APPENDED
17976	ACCEPT	AUTOMATIC_AFTER_VALIDATION
17981	LINK_EVIDENCE	by 1efd24fe (accepted)
17983	TASK_RESULT	by 1efd24fe (accepted)
18005	LINK_EVIDENCE	by 1efd24fe (accepted)
25377	TASK_RESULT	by 1efd24fe (accepted)

Score trace

{
  "claim": "93470326-1b64-8f1c-9bd1-6cd20acba021",
  "links": [
    {
      "link": "5e110b0a-67aa-8e45-bc10-7a0cf3e8f5bc",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "6f7fcb39-9947-8604-a284-7b6764abec3e",
      "direction": "QUALIFY",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "814c9da7-cf79-8afe-b8a8-f60628ae72b7",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "e1bfb962-2f31-8537-922f-dc8ae4e290fb",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DATASET_RESULT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    },
    {
      "link": "9aee8b0a-474b-83bb-8e2f-c3c91897294b",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "f3d56f0b-dd07-86a7-bdb8-117c33a096c2",
      "direction": "SUPPORT",
      "magnitude": "1.080000",
      "relevance": "STRONG",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "SECONDARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.080000",
      "interpretive_steps": 0
    },
    {
      "kept": "814c9da7-cf79-8afe-b8a8-f60628ae72b7",
      "link": "d71bf60d-3c49-83f4-900d-639b434d220c",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "6be961e5-f63a-8cb2-9707-7f7630879a77",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DATASET_RESULT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.0944",
    "permissive": "0.9769",
    "conservative": "0.8825"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "HIGH",
  "claim_type": "QUANTITATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.9468",
  "provisional": true,
  "evidence_sum": "2.880000",
  "snapshot_seq": 25378,
  "prior_log_odds": "0.000000",
  "support_groups": 2,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "5e110b0a-67aa-8e45-bc10-7a0cf3e8f5bc",
        "814c9da7-cf79-8afe-b8a8-f60628ae72b7",
        "d71bf60d-3c49-83f4-900d-639b434d220c"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "2.880000",
  "not_applicable_reason": null,
  "independence_unreviewed": 4
}